Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063023 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Oral Contraceptive Pill (OCP)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01063023 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 20 participants.
The verdict
NCT01063023, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
To assess the effects of BMS-650032 on Pharmacokinetics (PK) of ethinyl estradiol (EE) and norelgestromin (NGMN) in healthy female subjects
Interventions
- DRUG Ortho Tri-Cyclen®
- DRUG BMS-650032
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01063023
The ClinicalTrials.gov registry entry for NCT01063023 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ortho Tri-Cyclen® is the first listed.
NCT01063023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01063023 about?
NCT01063023 is a clinical study titled "Drug Interaction Oral Contraceptive Pill (OCP)". To assess the effects of BMS-650032 on Pharmacokinetics (PK) of ethinyl estradiol (EE) and norelgestromin (NGMN) in healthy female subjects
What is the current status of trial NCT01063023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01063023?
The interventions under investigation include: Ortho Tri-Cyclen® (DRUG), BMS-650032 (DRUG).
Who is sponsoring clinical trial NCT01063023?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.